Skip to main content
. 2022 Jun 11;14(12):2884. doi: 10.3390/cancers14122884

Table 3.

Representative anti-inflammatory cytokines relevant to pro-tumoral and therapeutic trials for HNSCCs.

Pro-Tumoral Activities Therapeutic Trials
IL-4 Elevation in HNSCC patients (* 76, 77, 78, 79) 81, 83
Protection of tumor cells (80)
IL-10 Elevation in HNSCC patients (85, 86)
Abrogation of anti-tumoral immunity (87)
Enhancement of Treg and M2 macrophage (88)
Activation of TAM (89)

* Numbers correspond to references in the text.